CAPE COD
In patients with severe community acquired pneumonia (CAP) does the use of hydrocortisone compared to a placebo reduce 28-day mortality?
Continue reading »A compendium of critical appraisals in Intensive Care Medicine research and related specialties
In patients with severe community acquired pneumonia (CAP) does the use of hydrocortisone compared to a placebo reduce 28-day mortality?
Continue reading »In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »In patients with severe COVID-19, does intravenous hydrocortisone (either as a fixed dose or restricted to when shock is clinically evident) compared with standard care, improve 21-day organ support free days?
Continue reading »In hospitalised patients with SARS-CoV-2 infection does dexamethasone in additional to usual care, compared to usual care alone, reduce 28-day mortality?
Continue reading »In critically ill patients with septic shock, does the combination of hydrocortisone plus fludrocortisone therapy reduce 90 day mortality?
Continue reading »In critically ill patients with septic shock, does hydrocortisone compared with placebo, reduce 90 day mortality?
Continue reading »In patients with septic shock, do corticosteroids compared to placebo reduce mortality?
This is an editorial blog post in anticipation of the ADRENAL trial results to be presented at #CCR18.
In patients with septic shock who are treated with corticosteroids, does tight glycaemic control (4.44–6.1 mmol/l) compared with less-tight glycaemic control (<8.3 mmol/l) reduce in-hospital mortality?
Continue reading »Does intravenous vitamin C, hydrocortisone and thiamine in addition to standard treatment, improve mortality in ICU patients with severe sepsis or septic shock, compared with standard treatment alone?
Continue reading »In patients with severe sepsis does hydrocortisone compared to placebo prevent the development of septic shock?
Continue reading »